How should supraventricular tachycardia that is not responding to adenosine and cardioversion be managed?

Management of Adenosine and Cardioversion-Refractory SVT

For hemodynamically stable patients with SVT refractory to adenosine and cardioversion, administer intravenous diltiazem or verapamil (64-98% effective), or intravenous beta-blockers as second-line pharmacologic therapy. 1

Immediate Assessment

First, verify the diagnosis and hemodynamic status:

• Confirm true SVT (not VT or pre-excited AF) - this is critical as calcium channel blockers can cause ventricular fibrillation in these conditions 1
• Reassess stability - if the patient has become unstable (hypotension, altered mental status, shock, chest pain, acute heart failure), repeat synchronized cardioversion immediately 1
• Check for pre-excitation on prior ECGs - if present, avoid AV nodal blockers 1

Algorithmic Approach Based on Hemodynamic Status

If Hemodynamically Unstable:

• Repeat synchronized cardioversion - this remains the definitive treatment and is highly effective 1
• Consider antiarrhythmic drugs to prevent immediate reinitiation after cardioversion (patients often have premature complexes that trigger recurrent SVT) 1
• Have resuscitative equipment immediately available

If Hemodynamically Stable:

First-line pharmacologic options (Class IIa recommendation):

• Intravenous diltiazem or verapamil - 64-98% conversion rate 1

  • Administer slowly over up to 20 minutes to minimize hypotension 1
  • Do NOT use if: suspected systolic heart failure, VT, or pre-excited AF 1

• Intravenous beta-blockers (esmolol, metoprolol) - reasonable alternative with excellent safety profile 1

  • Less effective than calcium channel blockers but safer in uncertain diagnoses 1

Second-line option (Class IIb):

• Intravenous amiodarone - may be considered when other therapies fail or are contraindicated 1
  • Effective in small studies but limited long-term toxicity with short-term use 1

Emerging evidence:

• Higher adenosine doses (24-36 mg) have shown success in case reports when standard dosing fails 2, 3
• Intravenous sotalol shows 50-90% conversion in refractory pediatric SVT, though adult data are limited 4

Critical Pitfalls to Avoid

1. Never give verapamil/diltiazem if:

   • Wide-complex tachycardia (may be VT)
   • Pre-excited AF visible
   • Systolic heart failure suspected
   • Risk of ventricular fibrillation in these scenarios 1

2. Adenosine can precipitate AF with rapid ventricular conduction - have cardioversion ready 1, 5

3. Post-conversion arrhythmias are common - premature complexes after cardioversion or drug conversion may immediately reinitiate SVT, requiring antiarrhythmic prophylaxis 1

4. Cardioversion failure suggests:

   • Wrong diagnosis (atrial flutter, focal AT, or automatic tachycardia)
   • Need for antiarrhythmic loading before repeat attempt
   • Consider cardiology consultation for definitive management

Important Nuances

The 2019 ESC guidelines 6 downgraded verapamil/diltiazem and no longer recommend amiodarone or digoxin for acute narrow-QRS tachycardias, though the 2015 ACC/AHA/HRS guidelines 1 still support these agents as reasonable options. The discrepancy reflects evolving evidence, but both guidelines agree that synchronized cardioversion remains definitive for refractory cases.

For truly refractory cases unresponsive to all standard therapies, case reports suggest magnesium sulfate (2g IV) as an unconventional rescue option 7, though this lacks guideline support and should only be considered when standard options have failed.

Next Steps After Acute Conversion

• Cardiology consultation for consideration of catheter ablation (definitive cure)
• Oral beta-blockers, diltiazem, or verapamil for ongoing management if ablation deferred 1
• Patient education on vagal maneuvers for future episodes